Search clinical trials for: KL1333 600 mg

Total 13891 results

Yungjin Pharm. Co., Ltd.

Completed

Safety, Tolerability and Pharmacokinetic Study of KL1333 in Healthy Male Volunteers

MELAS Syndrome | Mitochondrial Respiratory Chain Deficiencies

Korea, Republic of
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

Tolerability and Pharmacokinetics of CSPCHA115 Capsules in Chinese Healthy Volunteers

Asthma; Allergic Rhinitis

China
JMackem Co., Ltd
Seoul National University Hospital

Recruiting

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Oral Administration of AJH-2947 in Healthy Korean and/or Caucasian Adult Male Subjects

Diabetic Neuropathies | Neuropathic Pain | Post Herpetic Neuralgia

Korea, Republic of
Gannex Pharma Co., Ltd.
Ascletis Pharmaceuticals Co., Ltd.

Recruiting

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC61in Subjects With Advanced Solid Tumors

Advanced Solid Tumors

United States
Guangdong Zhongsheng Pharmaceutical Co., Ltd.

Completed

The Safety, Tolerability and Pharmacokinetic Study of ZSP1273 in Healthy Volunteers.

Influenza

China
Guangdong Raynovent Biotech Co., Ltd

Completed

Study of ZSP1273 in Patients With Acute Uncomplicated Influenza A

Influenza A

China
Pfizer

Withdrawn

A Study To Evaluate The Safety And Efficacy Of PF-06826647 In Participants With Moderate To Severe Ulcerative Colitis

Ulcerative Colitis

United States
Ilkos Therapeutic Inc.

Completed

Dose-response Relationship Study of S42909 on Leg Ulcer Healing

Venous Leg Ulcer

Spain, Hungary, Canada, United States, Brazil, Argentina, Austria, Czechia, Italy, Poland, Slovakia
CVI Pharmaceuticals

Unknown

Safety and Efficacy of CVI-LM001 in Patients With Hypercholesterolemia

Hyperlipidemia

China
NeuroBo Pharmaceuticals Inc.

Completed

Efficacy and Safety of Gemcabene in Patients With Low HDL-C and Either Normal or Elevated Triglycerides

Hypercholesterolemia | Hypertriglyceridemia
Janssen Research & Development, LLC

Completed

A Safety and Pharmacokinetics Study of CNTO 3157 in Healthy Japanese and Caucasian Participants

Healthy

United States
Global Alliance for TB Drug Development

Completed

A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of TBI-223 in Healthy Adults

Tuberculosis | Tuberculosis, Pulmonary

United States
Tibotec Pharmaceuticals, Ireland

Withdrawn

PEPI-TiDP23-C104 is a First in Human Study With a Single Dose Escalation Part and a Multiple Dosing Part for Compounds TMC589337 and TMC589354.

HIV Infections

Netherlands
Lexicon Pharmaceuticals

Completed

A Study to Determine the Safety and Efficacy of LX3305 in Subjects With Active Rheumatoid Arthritis

Rheumatoid Arthritis

United States
GlaxoSmithKline

Completed

A Dose Ranging Study to Evaluate the Safety and Efficacy of GSK2586184 in Patients With Chronic Plaque Psoriasis

Psoriasis

Germany, United Kingdom
Zhejiang Hisun Pharmaceutical Co. Ltd.

Unknown

Trial of Ginsenoside Compound K (GCK) Tablet in Patients With Rheumatoid Arthritis

Early Rheumatoid Arthritis

China
Innovation Pharmaceuticals, Inc.

Completed

Efficacy and Safety of Prurisol Administered Orally for Active Moderate to Severe Chronic Plaque Psoriasis

Chronic Stable Plaque Psoriasis

United States
Ascentage Pharma Group Inc.

Recruiting

APG-2575 Single Agent or in Combination With Ibrutinib or Rituximab in Patients With Waldenström Macroglobulinemia (MAPLE-1)

Waldenstrom Macroglobulinemia

United States, China, Australia
Galapagos NV

Completed

A Study to Evaluate Multiple Doses of GLPG2222 in Adult Subjects With Cystic Fibrosis

Cystic Fibrosis

Spain, United Kingdom, United States, Netherlands, Belgium, Serbia
GlaxoSmithKline

Terminated

An Adaptive Phase II Study to Evaluate the Efficacy, Pharmacodynamics, Safety and Tolerability of GSK2586184

Systemic Lupus Erythematosus

Estonia, Germany, South Africa, Peru, Sweden, France, Korea, Republic of, Hong Kong, Spain, Romania, Czechia, Argentina, Chile, Hungary, Greece, Poland
Merck Sharp & Dohme LLC

Completed

A Multiple-Dose Study to Evaluate MK-1075 in Hepatitis C Virus (HCV) Infected Participants (MK-1075-004)

Hepatitis C Virus Infection
Ardea Biosciences, Inc.

Completed

Naïve HIV POC Monotherapy Trial

HIV Infections

Germany, United Kingdom
Shire

Completed

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Single Oral Dose of Maribavir Administered in Healthy Japanese Participants Compared With Matched, Healthy, Non-Hispanic, Caucasian Participants and to Assess Dose-Proportionality of 3 Doses of Maribavir in Japanese Participants

Healthy Volunteers

United States
Spinifex Pharmaceuticals Pty Ltd
Syneos Health

Withdrawn

Dose Ranging Trial to Determine the Safety and Efficacy of EMA401 in Patients With PHN

Neuralgia, Postherpetic
Innovative Molecules GmbH

Recruiting

Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Doses of IM-250 in Healthy Volunteers

Herpes Simplex Virus

Germany
AbbVie

Completed

A Study to Investigate How Well Ravagalimab (ABBV-323) Works and How Safe it is in Participants With Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy

Ulcerative Colitis (UC)

United States, Canada, France, Germany, Hungary, Italy, Korea, Republic of, Netherlands, Spain, United Kingdom
MedImmune LLC

Completed

A Study to Evaluate the Efficacy of MEDI8968 in Chronic Obstructive Pulmonary Disease (SPRING)

Chronic Obstructive Pulmonary Disease

United States, Bulgaria, Czech Republic, Poland, United Kingdom, Philippines, Latvia, Lithuania, Ukraine, Hungary
Dr. Reddy's Laboratories Limited

Completed

A Study to Assess the Efficacy and Safety of PPC-06 (Tepilamide Fumarate)

Psoriasis

United States
GlaxoSmithKline

Completed

Single Dose Escalation First Time in Human PK Study

Infections, Bacterial

Australia
Transposon Therapeutics, Inc.

Active, not recruiting

A Phase 2a Study of TPN-101 in Patients With Progressive Supranuclear Palsy (PSP)

Progressive Supranuclear Palsy

United States
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Assess the Tolerability, Safety, Pharmacodynamics, and Pharmacokinetics of Ascending Single Doses (Including Food Interaction) and Ascending Multiple Doses of ACT-453859, and Multiple Doses of Setipiprant (ACT-129968)

Healthy
Vedic Lifesciences Pvt. Ltd.

Recruiting

A Study for Assessing the Efficacy and Safety ParActin® in Individuals With Upper Respiratory Tract Infections

Upper Respiratory Tract Infections

India
MacroGenics

Completed

A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms

Cervical Cancer | Hematologic Neoplasms | Ovarian Cancer | Non Small Cell Lung Cancer | Advanced Solid Tumors | Squamous Cell Carcinoma of Head and Neck | Cholangiocarcinoma | Small-cell Lung Cancer | TNBC - Triple-Negative Breast Cancer | HER2-positive Advanced Solid Tumors

Hong Kong, United States, Thailand, Australia, Spain, Bulgaria, Poland, Ukraine
UCB Pharma

Completed

Study Evaluating the Pharmacokinetics and Safety of Epratuzumab in Japanese Systemic Lupus Erythematosus (SLE)

Systemic Lupus Erythematosus

Japan
Merck Sharp & Dohme LLC

Completed

A Single Rising Dose Study of MK-8150 (MK-8150-001)

Hypertension | Isolated Systolic Hypertension (ISH)
Janssen Research & Development, LLC

Completed

A Study to Assess the Relative Oral Bioavailability of JNJ-63623872 Administered as Oral Concept Formulations Compared to the Current Tablet Formulation

Influenza A Virus

Belgium
AstraZeneca

Completed

A Study to Assess Safety and Tolerability of Oral AZD3241 in Patients With Parkinson's Disease

Parkinson's Disease

United States
NanOlogy, LLC
US Biotest, Inc.

Terminated

Phase II Study of Intraperitoneal NanoPac® in Patients With Ovarian Cancer

Ovarian Carcinoma

United States
Impax Laboratories, LLC

Completed

Pharmacokinetics and Pharmacodynamics of IPX054 in Subjects With Parkinson's Disease

Idiopathic Parkinson's Disease

United States
Boehringer Ingelheim

Completed

This Study is Done in Patients With Plaque Psoriasis and Tests How Well They Tolerate BI 730357 and How Effective it is

Psoriasis

United States, Canada, Germany
SIGA Technologies
National Institutes of Health (NIH)

Completed

Safety, Tolerability, Pharmacokinetics (PK) of the Anti-Orthopox Drug, ST-246 (246-Safety)

Orthopoxviral Disease

United States
Aevi Genomic Medicine, LLC, a Cerecor company

Completed

Pharmacokinetic and Tolerability Study of NFC-1 in Subjects Aged 6-17 Years With ADHD

Attention Deficit Disorder With Hyperactivity

United States
Abliva AB

Completed

A Phase Ia/Ib, SAD and MAD Study of of KL1333 in Healthy Subjects and Patients With Primary Mitochondrial Disease

Mitochondrial Diseases | Mitochondrial Myopathies | MELAS Syndrome | Mitochondrial Respiratory Chain Deficiencies

United Kingdom
CymaBay Therapeutics, Inc.

Completed

Study Investigating the Safety, Tolerability, and PK, PD, of CB-0406

Healthy Volunteers

Australia
Bayer
Amgen

Completed

Study to Determine the Safety, Maximum Tolerated Dose, Pharmacokinetics of Sorafenib (BAY43-9006)

Carcinoma

United States
Altavant Sciences GmbH
Parexel; Altavant Sciences, Inc.

Completed

Multiple-Ascending Dose in Japanese Patients Bridging Study

Healthy

United States
Khon Kaen University
Government Pharmaceutical Organization

Completed

Effect of Bacopa Monnieri on Working Memory and Cognitive Processing in Student

Healthy

Thailand
Abliva AB

Active, not recruiting

Efficacy of KL1333 in Adult Patients With Primary Mitochondrial Disease (FALCON)

Primary Mitochondrial Disease

Belgium, United Kingdom, United States, Spain, Denmark, France
Janssen Infectious Diseases BVBA

Completed

A Study to Investigate Safety, Tolerability, and Pharmacokinetics of JNJ-63623872 in Healthy Japanese Adult Participants

Healthy

United Kingdom
National Institute of Allergy and Infectious Diseases...

Recruiting

Linezolid Dosing Strategies in Drug-Resistant TB

Tuberculosis | Tuberculosis, Pulmonary | Tuberculosis, Multidrug-Resistant

Brazil, India, Kenya, Philippines, South Africa, Zimbabwe, Thailand, Haiti, Peru, Botswana

Search clinical trials for: KL1333 600 mg

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ethiopia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations